CROI 2015 Program and Abstracts

Poster Listings

566 Virological Responses to Lamivudine and Emtricitabine in the Nationwide ATHENA Cohort Casper Rokx 1 ; Azzania Fibriani 1 ; David A. van deVijver 1 ; AnneliesVerbon 1 ; Martin Schutten 1 ; Luuk Gras 2 ; Bart J. Rijnders 1 On behalf of the Dutch HIV Monitoring Foundation 1 Erasmus University Medical Center, Rotterdam, Netherlands; 2 Academic Medical Center University of Amsterdam, Amsterdam, Netherlands 567 Prevalence and Risk Factors of Multiple Micronutrient Deficiencies Pre- and Post-ART Rupak Shivakoti 1 ; Parul Christian 2 ; Nikhil Gupte 1 ; Cecilia Kanyama 3 ; Sima Berendes 4 ; Javier Lama 5 ; Richard Semba 1 ;Thomas Campbell 6 ; Amita Gupta 1 NWCS 319 and PEARLS StudyTeam 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3 University of North Carolina Project–Malawi, Lilongwe, Malawi; 4 Malawi College of Medicine-Johns Hopkins University Research Project, Blantyre, Malawi; 5 Asociacion Civil Impacta Salud y Educacion, Lima, Peru; 6 University of Colorado School of Medicine, Aurora, CO, US 568 Detection of HIV RNA and DNA in Anal Swabs of HIV Infected Men Having Sex With Men Julian Storim 1 ; Jens Verheyen 1 ; EvaWolff 1 ; Lewin Eisele 1 ; JeremiasWohlschläger 2 ; Peter- Michael Rath 1 ; Evelyn Heintschel von Heinegg 1 ; Dirk Schadendorf 1 ; Stefan Esser 1 1 University Hospital Essen, University Duisburg-Essen, Essen, Germany; 2 University Hospital Essen, Essen, Germany 2:30 pm– 4:00 pm ART: Immunologic Response—The Good and The Bad 569 Reference Curves for CD4 Response to Antiretroviral Treatment in HIV-1– Infected Naïve Patients Rodolphe Thiebaut On behalf of the Standard Reference Distribution of CD4Working Group in COHERE in EuroCoord Bordeaux University, Bordeaux, France 570 Comparing Immunological Failure Definitions, Using Tanzanian National HIV Data Fiona Vanobberghen 1 ; Bonita K. Kilama 2 ; AlisonWringe 1 ; Angela Ramadhani 2 ; Basia Zaba 1 ; Donan Mmbando 3 ; JimTodd 1 1 London School of Hygiene and Tropical Medicine, London, United Kingdom; 2 National AIDS Control Program, Dar es Salaam, United Republic of Tanzania; 3 Ministry of Health & Social Welfare, Dar es Salaam, United Republic of Tanzania 571 Delaying Second-Line Therapy After First-Line Failure: Moderating Effect of CD4 Count Julia K. Rohr 1 ; Prudence Ive 2 ; Rebecca H. Berhanu 3 ; Kate Shearer 2 ; Mhairi Maskew 2 ; Lawrence Long 2 ; Ian Sanne 2 ; Matthew P. Fox 1 1 Boston University School of Public Health, Boston, MA, US; 2 University of Witswatersrand, Johannesburg, South Africa; 3 Right to Care, Johannesburg, South Africa 572 Rapid Progression Hinders the Recovery of CD4 + T Cells Following Initiation of cART Inma Jarrin On behalf of the CASCADE Collaboration within EUROCOORD Instituto de Salud Carlos III, Madrid, Spain 573 Increase in CD4 Counts at Presentation to ART Care Among Urban HIV Clinics in Uganda ELIZABETH K. NALINTYA 1 ; Agnes N. Kiragga 1 ; Edison Katunguka 2 ; HenryW. Nabeta 1 ; Joanita Kigozi 1 ;Yukari Manabe 4 ; David R. Boulware 2 ; Jon Kaplan 3 ; David B. Meya 1 1 Infectious Diseases Institute, Kampala Uganda, Kampala, Uganda; 2 University of Minnesota, Minneapolis, MN, US; 3 CDC Center for Global Health, Division of Global AIDS/HIV, Atlanta, GA, US; 4 Johns Hopkins University, Baltimore, MD, US WEDNESDAY, FEBRUARY 25, 2015 Session P-K3 Poster Session Poster Hall

574 Implications of Poor CD4 Recovery During HIV Suppressive ART in Sub- Saharan Africa Marieke E. de Pundert 1 ;Tamara Sonia Boender 1 ; Raph L. Hamers 1 ; Kim Sigaloff 1 ; Cissy M. Kityo 2 ; Alani S. Akanmu 3 ; MaureenWellington 4 ;Tobias F. Rinke deWIt 1 ; Pascale Ondoa 1 Pan African Studies to Evaluate Resistance (PASER) studygroup 1 Amsterdam Institute for Global Health and Development, Brasschaat, Belgium; 2 Joint Clinical Research Centre Kampala, Kampala, Uganda; 3 Lagos University Teaching Hospital, Lagos, Nigeria; 4 Newlands Clinic, Harare, Zimbabwe 575 Better CD4/CD8 Restoration in First-Line HIV-Infected CMV-Seronegative Patients Isabelle Poizot-Martin 1 ; Clotilde Allavena 2 ; Claudine Duvivier 3 ; Carla E. Cano 1 ; Francine Guillouet de Salvador 4 ; David Rey 5 ; Lise Cuzin 6 ; Antoine Cheret 7 ; Bruno Hoen 8 On behalf of the Dat’AIDS Group 1 Aix-Marseille Univ, APHM Hôpital Sainte-Marguerite, Marseille, France; 2 CHU Hotel Dieu, Nantes, France; 3 APHP–Hopital Necker–Université Paris Descartes–IHU Imagine, Paris, France; 4 CHU Archet 1, Nice, France; 5 Hôpitaux Universitaires Strasbourg, Strasbourg, France; 6 Regional Coordination for HIV, Toulouse, France; 7 Hospital Tourcoing, Tourcoing, France; 8 University Medical Center of Guadeloupe, Guadeloupe, France; 9 The Dat’AIDS Group, Nice, France 576 CD4 Response in Treatment-Naïve HIV-2 – Infected Patients: The IeDEA West Africa Cohort Eric Balestre 1 ; Koumavi K. Ekouevi 2 ; BorisTchounga 2 ; Serge P. Eholié 3 ; Eugène Messou 4 ; Adrien Sawadogo 5 ; RodolpheThiebaut 1 ; MargaretT. May 6 ; Jonathan A. Sterne 6 ; François Dabis 1 1 Univ Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France; 2 Programme PAC-CI, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; 3 Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; 4 Centre de Prise en Charge de Recherche et de Formation, Hôpital Yopougon Attié, Abidjan, Côte d’Ivoire; 5 Institut Supérieur des Sciences de la Santé, Université Polytechnique de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso; 6 School of Social and Community Medicine, Bristol University, Bristol, United Kingdom 2:30 pm– 4:00 pm ART: Mortality 577 Mortality and Retention After 12 Months in a Cohort of Patients InitiatedWith the NewWHO Recommendations in Uganda John Ssali; Juan Gonzalez Perez; Jonathan Ikapule; Lydia Buzaalirwa; Kate Ssamula; Augustine Lubanga; Sulaiman Kawooya; Monday Busuulwa; Penninah Lutung Amor; Michael Wohlfeiler AIDS Healthcare Foundation, Kampala, Uganda 578 Effect of ART on Mortality Generalized to Newly HIV-Diagnosed Persons in the USA Catherine R. Lesko 1 ; Stephen R. Cole 1 ; H. Irene Hall 3 ; Michael J. Mugavero 2 1 University of North Carolina, Chapel Hill, NC, US; 2 University of Alabama at Birmingham, Birmingham, AL, US; 3 US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 579 Association of CD4:CD8With Cause-Specific Mortality in Patients on Long-Term ART Margaret T. May 1 ; AdamTrickey 1 ; Dominique Costagliola 6 ; Peter Reiss 4 ; Santiago Moreno 5 ; 1 University of Bristol, Bristol, United Kingdom; 2 University College London, London, United Kingdom; 3 University of Calgary, Calgary, Canada; 4 Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 5 Hospital Ramón y Cajal, Madrid, Spain; 6 UMR S 1136, Inserm et Sorbonne Universités, Université Pierre et Marie Curie, Paris, France 580 Outcomes of First ART in Latino Populations in North America and Latin America Carina T. Cesar 1 ; Mark J. Giganti 2 ; Bryan E. Shepherd 2 ; Richard Moore 3 ; Keri N. Althoff 3 ; Sonia Napravnik 4 ; Angel M. Mayor 5 ; Catherine Mc Gowan 2 ; Pedro E. Cahn 1 1 Fundacion Huesped, Buenos Aires, Argentina; 2 Vanderbilt University, Nashville, TN, US; 3 Johns Hopkins University, Baltimore, MD, US; 4 University of North Carolina, Chapel Hill, NC, US; 5 Retrovirus Research Center, Bayamon, US Session P-K4 Poster Session John Gill 3 ; Colette Smith 2 ; Suzanne M. Ingle 1 ; Jonathan A. Sterne 1 On behalf of the AntiretroviralTherapy Cohort Collaboration (ART-CC)

Poster Listings

Poster Hall

47

CROI 2015